<DOC>
	<DOCNO>NCT02919306</DOCNO>
	<brief_summary>The purpose study ass : 1 safety tolerability adenovirus serotype 26 ( Ad26 ) prime Modified Vaccinia Ankara ( MVA ) boost versus placebo participant suppressive antiretroviral therapy ( ART ) initiate acute Human Immunodeficiency Virus ( HIV ) infection ; 2 ) Measure frequency duration sustain viremic control receive Ad26 prime/MVA boost placebo , define great 24 week plasma HIV ribonucleic acid ( RNA ) lesser ( &lt; ) 50 copies/ml antiretroviral ( ARV ) analytical treatment interruption ( ATI ) .</brief_summary>
	<brief_title>Safety Efficacy Study Vaccine Schedule With Ad26.Mos.HIV MVA-Mosaic Human Immunodeficiency Virus ( HIV ) -Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Confirmed human immunodeficiency virus ( HIV ) 1 infect start antiretroviral therapy ( ART ) acute infection ( Fiebig stag I , II , III IV ) part trial RV254 Treatment current stable antiretroviral therapy ( ART ) ( change treatment ) least 4 week prior screen All female participant childbearing potential must negative serum pregnancy test ( beta human chorionic gonadotropin ) screen visit , negative urine pregnancy test prior vaccination Day 1 prior subsequent study vaccination HIV ribonucleic acid ( RNA ) less ( &lt; ) 50 copy per milliliter ( copies/ml ) least 48 week screen : ) One blip HIV RNA great ( &gt; ) 50 &lt; 200 copies/ml within 48 week acceptable , provide recent ( screen ) HIV RNA &lt; 50 copies/ml Laboratory criterion screen : ) Hemoglobin : Women : great equal &gt; =11 gram/deciliter ( g/dL ) ; Men &gt; =12.5 g/dL , b ) White cell count : 2,500 11,000 cell per cubic millimeter ( cells/mm^3 ) , c ) Platelets : 125,000 450,000 per mm^3 , ) Alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) less equal &lt; =1.5x institutional upper limit normal ( ULN ) , e ) Creatinine &lt; =1.5x institutional ULN , f ) CD4 &gt; 400 cells/mm^3 , g ) Troponin &lt; 1x ULN A woman must either : ) Not childbearing potential : postmenopausal ( &gt; 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulation hormone [ FSH ] level &gt; 40 International Units Per Liter ( IU/L ) ; surgically sterile ; b ) Of childbearing potential practicing effective double method birth control ( example , prescription oral contraceptive , contraceptive injection , intrauterine device , contraceptive patch , vaginal ring , conjunction either female condom one method male contraception entry 3 month last vaccination Receipt vaccine within 30 day prior first vaccination plan receive within 30 day postvaccination . In case medically indicate vaccine , vaccination give least 2 week first vaccination . However , vaccine indicate post exposure setting ( example , rabies tetanus ) , must take priority study vaccine rule apply subsequent study vaccination Any history HIVrelated illness Centers Disease Control Prevention ( CDC ) category C History myocarditis , pericarditis , cardiomyopathy , congestive heart failure permanent sequela , clinically significant arrhythmia ( include arrhythmia require medication , treatment , clinical followup ) Chronic active hepatitis B active hepatitis C ( example , positive serology confirmatory positive polymerase chain reaction ) active syphilis infection . Active syphilis document examination serology unless positive serology due past treated infection Receipt blood product immunoglobulin past 3 month History anaphylaxis serious adverse reaction vaccine vaccine product , neomycin streptomycin egg product History chronic urticaria ( recurrent hive ) Chronic recurrent use medication modify host immune response , example ( e.g . ) cancer chemotherapeutic agent , parenteral corticosteroid ( short course oral steroid give nonchronic condition expect recur exclusion criterion , topical steroid use exclusion criterion ) , etc . include ART</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>